Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | ASPH | Q12797 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.32 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | LDHB | P07195 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5114983 | 0.82 | ALDH1A1 (0.34) | KDM4EPKM | |
| SCHEMBL16637048 | 0.78 | NPSR1 (0.41) | KDM4EPKMNPC1L3MBTL1 | |
| SCHEMBL7983978 | 0.78 | CFTR (0.40) | PKM | |
| SCHEMBL27715188 | 0.78 | PKM (0.31) | KDM4EPKM | |
| SCHEMBL5113693 | 0.78 | GSK3B (0.40) | KDM4E | |
| SCHEMBL23366909 | 0.78 | CYP1A2 (0.32) | KDM4E | |
| Hydrochloric Acid SCHEMBL23354097 | 0.77 | LMNA (0.33) | KDM4E | |
| SCHEMBL23354458 | 0.77 | ALDH1A1 (0.33) | KDM4EPKM | |
| SCHEMBL23354538 | 0.72 | MEN1 (0.31) | L3MBTL1 | |
| SCHEMBL20783705 | 0.72 | KDM4E (0.70) | KDM4EPKMDAOTDP1ASPH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2025-08-26 | — | — | US | disclosed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| EP-4058448-B1 | HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER AG (DE) | 2024-05-29 | — | — | EP | disclosed |
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| EP-4058446-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2022-09-21 | — | — | EP | disclosed |
| EP-4058448-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2022-09-21 | — | — | EP | disclosed |
| WO-2021094434-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021094436-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | WO | disclosed |
| EP-3822265-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer AG (DE) | 2021-05-19 | — | — | EP | disclosed |
| CN-108383858-A | Treat the derivative of the imidazo thiadiazoles and Imidazopyrazines of platelet aggregation | 百时美施贵宝公司 | 2018-08-10 | — | — | CN | disclosed |
| CN-104583218-B | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4(PAR4) inhibitors for the treatment of platelet aggregation | 百时美施贵宝公司 | 2018-04-24 | — | — | CN | disclosed |
| CN-105612162-A | Thiazolopyrimidinones as modulators of NMDA receptor activity | HOFFMANN LA ROCHE | 2016-05-25 | — | — | CN | disclosed |
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-05-29 | — | — | US | disclosed |
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | NEUROGEN CORPORATION (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | NEUROGEN CORPORATION (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | NEUROGEN CORPORATION (US) | 2008-04-10 | — | — | US | disclosed |
| CN-101103028-A | Heteroaryl substituted quinolin-4-ylamine analogues | NEUROGEN CORP (US) | 2008-01-09 | — | — | CN | disclosed |
| EP-1836203-A2 | HETEROARYL SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006076646-A2 | HETEROARYL SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ADAMTS7, MMP7, ADAMTS1 | KDM4E 2923/4885PKM 2203/4885DAO 164/4885 |
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | ADAMTS7, MMP7, ADAM17 | KDM4E 3062/4885PKM 2909/4885DAO 144/4885 |
| US-20080085901-A1 | Heteroaryl Substituted Quinolin-4-Ylamine Analogues | PIGS, GPR52, GPR174 | KDM4E 2834/4885PKM 2544/4885DAO 1184/4885 |
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | PIGO, GPR52, GPR88 | KDM4E 3422/4885PKM 1332/4885DAO 1555/4885 |
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ADAMTS7, MMP7, ADAM17 | KDM4E 3062/4885PKM 2909/4885DAO 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.